HSANZ Free Communications 9: Low-grade lymphoma
Tracks
HSANZ
| Tuesday, October 20, 2026 |
| 10:30 AM - 12:00 PM |
Speaker
Mr Dion Marinkovich
Sr Advisor – Medical Affairs
Eli Lilly and Company
Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL): results from the phase 1/2 BRUIN study (final update)
10:30 AM - 10:45 AM
Ms Rachel Lou
Medical Student
Monash University
Real world outcomes in hairy cell leukaemia (HCL): A single centre experience
10:45 AM - 11:00 AM
Prof Judith Trotman
Hematologist
Concord Repatriation General Hospital, University Of Sydney
BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory Waldenström macroglobulinemia in the CaDAnCe-101 study
11:00 AM - 11:15 AM
Dr Shin Hnin Wai
Lymphoma Fellow
The Alfred Hospital
Follicular lymphoma with Clinically aggressive features, Discordant to the Indolent Histology has greater risk of transformation.
11:15 AM - 11:30 AM
Dr Ricky Nelles
Haematologist
Royal Brisbane and Women's Hospital
Centroblast score companion biomarker improves FDG-PET prognostication to guide frontline therapy in follicular lymphoma
11:30 AM - 11:45 AM
Dr Nathanael Lucas
Paediatric Haematologist
Starship Hospital
HAVCR2-associated subcutaneous panniculitis T-cell lymphoma in Auckland – A quality improvement audit and next steps
11:45 AM - 12:00 PM
